AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 31 min read$IRTC

Tax-withholding stock sale by iRhythm (IRTC) CFO

iRhythm (IRTC) CFO Daniel Wilson sold 773 shares at $121.83 each on September 2, 2026, to cover tax withholding from RSU vesting. He retains 34,887 direct shares and 100 indirect shares. The sale was not under a 10b5-1 plan.

Original reporting
stocktitan.net
Published Sep 3, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 3:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IRTC
Neutral
high confidence
Mentioned
$IRTC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The CFO's sale is routine and small, offering limited trading insight.

02

Market read

Minor insider sale with negligible market impact.

03

What to watch

Potential upcoming RSU vesting schedule could lead to further insider sales.

Relevance 4/10Novelty 4/10Timing: post‑market September 2, 2026

Background

Form 4 filing discloses insider transactions; traders monitor for material changes.

Company-level read

Ticker impact

$IRTCNeutralHigh confidence
Context

CFO Daniel G. Wilson sold 773 shares at $121.83 to cover tax withholding on RSU vesting, holding 34,987 shares thereafter.

Expected impact

minimal impact, potential slight downward pressure

Evidence & confidence

The transaction size (~$94K) is trivial for a public company and no plan indicates urgency.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale may signal insider confidence despite being a routine tax withholding transaction.

Key entities

  • Executive
    Daniel G. Wilson

    Chief Financial Officer of iRhythm Holdings

Read at source← All news

Related articles

SEP 14
$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min
AUG 16
$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

aol.com6 min